Tan Brandon E K, Tham Seng Kong, Poh Chit Laa
ALPS Global Holding Berhad, The Icon, East Wing Tower Level 18-01 & Level 18-02, No.1 Jalan 1/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia.
Nilai University, No.1, Persiaran Universiti, Putra Nilai, Bandar Baru Nilai, Nilai 71800, Negeri Sembilan, Malaysia.
Viruses. 2025 Jul 8;17(7):960. doi: 10.3390/v17070960.
Zoonotic diseases are transmitted from animals to humans, and they impose a significant global burden by impacting both animal and human health. It can lead to substantial economic losses and cause millions of human deaths. The emergence and re-emergence of zoonotic diseases are heavily influenced by both anthropogenic and natural drivers such as climate change, rapid urbanization, and widespread travel. Over time, the unprecedented rise of new and re-emerging zoonotic diseases has prompted the need for rapid and effective vaccine development. Following the success of the COVID-19 mRNA vaccines, mRNA-based platforms hold great promise due to their rapid design, swift development and ability to elicit robust immune responses, thereby highlighting their potential in combating emerging and pre-pandemic zoonotic viruses. In recent years, several mRNA vaccines targeting emerging and re-emerging zoonotic viral diseases, such as rabies, Nipah, Zika, and influenza, have advanced to clinical trials, demonstrating promising immunogenicity. This review explores recent advances, challenges, and future directions in developing mRNA vaccines against emerging and re-emerging zoonotic viral diseases.
人畜共患疾病从动物传播给人类，通过影响动物和人类健康给全球带来重大负担。它可导致巨大的经济损失，并造成数百万人死亡。人畜共患疾病的出现和再度出现受到气候变化、快速城市化和广泛旅行等人造和自然因素的严重影响。随着时间的推移，新型和再度出现的人畜共患疾病前所未有的增加促使人们需要快速有效地开发疫苗。继新冠mRNA疫苗取得成功之后，基于mRNA的平台因其设计迅速、开发快捷以及能够引发强大免疫反应而极具前景，从而凸显了它们在对抗新出现和大流行前的人畜共患病毒方面的潜力。近年来，几种针对狂犬病、尼帕病毒、寨卡病毒和流感等新出现和再度出现的人畜共患病毒性疾病的mRNA疫苗已进入临床试验阶段，显示出有前景的免疫原性。本综述探讨了开发针对新出现和再度出现的人畜共患病毒性疾病的mRNA疫苗的最新进展、挑战和未来方向。
